新型抗肿瘤免疫治疗药物研究进展

doi:10.19803/j.1672-8629.2021.08.05

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (8): 719-724.
DOI: 10.19803/j.1672-8629.2021.08.05

• 新型抗肿瘤药物利用、风险性与经济性研究专栏 • 上一篇下一篇

新型抗肿瘤免疫治疗药物研究进展

鲍柏屹^1,2, 汤贯光², 王兴伟², 唐书炳², 李歆^1,3#, 韩峰^1,*

¹南京医科大学药学院, 江苏南京 211166;
²成都地奥制药集团,四川成都 610041;
³南京医科大学全球健康中心, 江苏南京 211166

收稿日期:2021-03-25 出版日期:2021-08-15 发布日期:2021-08-17
通讯作者: ^*韩峰,男,二级教授·博导,临床药理学。E-mail：fenghan169@njmu.edu.cn ^#为共同通信作者。
作者简介:鲍柏屹,男,硕士,临床药学。
基金资助:
国家自然科学基金资助项目（72074123,716731471）; 江苏省政策引导类计划（软科学研究）（BR2020043）

Research Progress on New Anti-tumor Immunotherapy Drugs

BAO Baiyi^1,2, TANG Guanguang², WANG Xingwei², TANG Shubing², LI Xin^1,3#, HAN Feng^1,*

¹School of Pharmacy, Nanjing Medical University, Nanjing Jiangsu 211166, China;
²Chengdu DIAO Group, Chengdu Sichuan 610041, China;
³Center for Global Health, Nanjing Medical University, Nanjing Jiangsu 211166, China

Received:2021-03-25 Online:2021-08-15 Published:2021-08-17

摘要/Abstract

摘要： 肿瘤是严重危害人类生命的医学难题,目前肿瘤的治疗手段包括手术治疗、放射治疗、化学药物治疗、靶向药物治疗、免疫治疗等。近年来,随着人们对肿瘤免疫研究的不断深入,免疫学、分子生物学等学科的不断发展,肿瘤免疫治疗在临床中显示出良好的临床价值和优势,在传统免疫抗肿瘤的治疗药物和疗法的基础之上,新型抗肿瘤免疫治疗药物迅速发展,具有巨大的研究价值和发展潜力。本文从肿瘤的免疫治疗出发,论述了目前新型抗肿瘤免疫治疗药物的基本类别和研究进展,同时对该类药物存在的问题以及我国在此领域面临的挑战进行了总结,以期为新型免疫抗肿瘤药物的研究、临床合理用药以及抗肿瘤治疗提供参考。

关键词: 肿瘤, 免疫治疗, PD1/PD-L1抑制剂, 肿瘤疫苗, CAR-T, 溶瘤病毒

Abstract: Tumors are difficult to cure and pose a serious threat to human lives. Current approaches to tumors include surgery, radiotherapy, chemotherapy, drugs targeting and immunotherapy. In recent years, with more research on tumor immunology and progress in such disciplines as immunology and molecular biology, immunological treatment of tumors has proved to be of good clinical value with advantages in clinical practice. Novel anti-tumor drugs for immunological treatment keep emerging and promise a good prospect of development. Based on the immunity treatment of tumor, this article discussed the basic categories and research progress regarding the new anti-tumor immunity treatment medicine. At the same time, the problems of this medicine and the challenges that China faces in this field were summarized to provide reference and help for the research of new anti-tumor immunity medicine, clinical reasonable medication and anti-tumor treatment.

Key words: tumor, immunotherapy, PD1/PD-L1 inhibitor, tumor vaccine, CAR-T, oncolytic virus

中图分类号:

R979.1

鲍柏屹, 汤贯光, 王兴伟, 唐书炳, 李歆, 韩峰. 新型抗肿瘤免疫治疗药物研究进展[J]. 中国药物警戒, 2021, 18(8): 719-724.

BAO Baiyi, TANG Guanguang, WANG Xingwei, TANG Shubing, LI Xin, HAN Feng. Research Progress on New Anti-tumor Immunotherapy Drugs[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 719-724.

参考文献

[1] Coley WB.The treatment of malignant tumors by repeated inocul-ations of erysipelas with a report of ten original cases[J]. Clinical Orthopaedics & Related Research, 1991, 262: 3-11.
[2] Ishida Y, Agata Y, Shibahara K, et al.Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. The EMBO Journal, 1992, 11(11): 3887-3895.
[3] Chen FX, Li X, Liu JQ, et al.Tumor immunoediting and immuno-therapy[J]. Medicine and Philosophy(肿瘤免疫编辑与免疫治疗), 2007, 28(04): 59-61
[4] Yang ZY, Du XL, He XJ, et al.Thymosin α1 combined with FOLFOX4 in the treatment of advanced hepatocellular carcinoma in a complete remission case[J].CMCR(中国临床案例成果数据库), 2020, 2(1): E077-E077.
[5] Zuo ZF.Thymosin α1 combined with immune checkpoint suppression in a case of advanced liver cancer[J]. CMCR(中国临床案例成果数据库), 2020, 2(1): E084-E084.
[6] Graziani G, Tentori L, Navarra P.Ipilimumab: a novel immunosti-mulatory monoclonal antibody for the treatment of cancer[J]. Pharmacological Research, 2012, 65(1): 9-22.
[7] Hodi FS, O'Day SJ, Mcdermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma[J]. New England Journal of Medicine, 2010, 363(8): 711-723.
[8] Lynch TJ, Bondarenko I, Luft A, et al.Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study[J]. Journal of Clinical Oncology, 2012, 30(17): 2046-2054.
[9] Reck M, Ciuleanu TE, Dols MC, et al.OA03. 02 Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (Chemo) vs. 4 cycles chemo as first-line (1L) treatment for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA[J]. Journal of Thoracic Oncology, 2020, 16(1): S2.
[10] Kahler KC, Hauschild A.Treatment and side effect managementf CTLA-4 antibody therapy in metastatic melanoma[J]. J Dtsch Dermatol Ges, 2011, 9(4): 277-286.
[11] Dillard T, Yedinak CG, Alumkal J, et al.ANTI-CTLA-4 anti-body therapy associated autoimmune hypophysitis: serious im-mune related adverse events across a spectrum of cancer subtypes[J]. Pituitary, 2010, 13: 29-38.
[12] Fadel F, El Karoui K, Knebelmann B.ANTI-CTLA4 antibody-induced lupus nephritis[J]. N Engl J Med, 2009, 361(2): 211-212.
[13] Li B, Vanroey M, Wang C, et al.Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors[J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2009, 15(5): 1623.
[14] Kaiser J, Couzin-Frankel J.Cancer immunotherapy sweeps Nobel for medicine[J]. Science, 2018, 362(6410): 13.
[15] Fan Y, Zhao J, Wang Q, et al.Camrelizumab Plus Apatinib in extensive-stage small-cell lung cancer (PASSION): a multicenter, two-stage, phase 2 trial[J]. Journal of Thoracic Oncology, 2020, 16(2): 299-309.
[16] Zhuo C, Chen G, Huang Y, et al.Camrelizumab Plus Carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial[J]. The hancet 2021, 9(3): 305-314.
[17] Tang B, Chi Z, Chen YB, et al. Safety, efficacy and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial[J]. Clinicalr Cancer Research, 2020, 26(16): clincancers. 3922. 2019.
[18] Wang FH, Wei XL, Feng J, et al. Efficacy, safety,correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02) [J]. Journal of Clinical Oncology, 2021, 39(7): JCO. 20. 02712.
[19] Shen L, Guo J, Zhang Q, et al.Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study[J]. Journal for Immunotherapy of Cancer, 2020, 8(1): e000437.
[20] Wang J, Yu X, Lu S, et al.Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC)[J]. Journal of Clinical Oncology, 2020, 38(15_suppl): 9554-9554.
[21] Huang X, Yang Y.Driving an improved CAR for cancer immuno-therapy[J]. Journal of Clinical Investigation, 2016, 126(8): 2795-2798.
[22] Fang J, Ding N, Guo X, et al.αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib[J]. Journal for Immunotherapy of Cancer, 2021, 9(2): e001162.
[23] Shi D, Shi Y, Kaseb AO, et al.Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials[J]. Clinical Cancer Research, 2020, 26(15): 3979-3989.
[24] Li Y, Hermanson DL, Moriarity BS, et al.Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity[J]. Cell Stem Cell, 2018, 23(2): 181-192.
[25] Guo C, Manjili MH, Subjeck JR, et al.Therapeutic cancer vaccines: past, present, and future[J]. Advances in Cancer Research, 2013, 119: 421.
[26] Butterfield LH.Cancer vaccines.[J]. BMJ, 2015, 350: h988.
[27] Young MD, Gooch WM 3rd, Zuckerman AJ, et al. Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination[J]. J Med Virol, 2001, 64(3): 290-298.
[28] Beran J.Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients[J]. Expert Opin Biol Ther. 2008; 8(2): 235-247.
[29] Charlton HHK, Vidigal J, Carrondo MJT, et al.Synthetic biology for bioengineering virus-like particle vaccines[J]. Biotechnol Bioeng, 2019, 116(4): 919-935.
[30] Ogi C, Aruga A.Clinical evaluation of therapeutic cancer vaccines[J]. Human Vaccines & Immunotherapeutics, 2013, 9(5): 1049-1057.
[31] Grekova SP, Aprahamian M, Daeffler L, et al.Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer[J]. Cancer Biol Ther, 2011, 12(10): 888-895.

新型抗肿瘤免疫治疗药物研究进展

Research Progress on New Anti-tumor Immunotherapy Drugs

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[2]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[3]	辛灵怡, 杨洋, 朱婧, 何娜, 张静媚, 王航天, 陈琴华, 杨光义. 重楼抗肿瘤活性成分分类及作用机制研究进展[J]. 中国药物警戒, 2024, 21(2): 235-240.
[4]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[5]	张亮亮, 胡昌坤, 吴泽坤, 周维, 廖泽彬, 高月. 富马酸二甲酯对肠道辐射损伤防护作用及机制研究[J]. 中国药物警戒, 2024, 21(1): 83-88.
[6]	熊玮仪, 任经天. 抗肿瘤药说明书安全性信息上市后修订的考虑要点[J]. 中国药物警戒, 2024, 21(1): 94-97.
[7]	张立, 汪余嘉, 张玲玲, 陈家鑫, 林敏华, 林小惠, 聂雪坤. 真实世界免疫检查点抑制剂相关不良反应监测数据分析[J]. 中国药物警戒, 2023, 20(9): 1035-1038.
[8]	何慧珍, 郭轶先, 孙婉玲. 靶向CD47治疗淋巴瘤研究进展[J]. 中国药物警戒, 2023, 20(9): 1071-1077.
[9]	何雄, 马俊龙, 阳国平. 基于FAERS对靶向HER2抗体偶联药品不良反应/事件的分析[J]. 中国药物警戒, 2023, 20(8): 915-920.
[10]	张夏兰, 袁静, 吴斌, 秦媛媛. 甲磺酸阿帕替尼在恶性肿瘤患者的用药特征分析[J]. 中国药物警戒, 2023, 20(8): 927-932.
[11]	郑轶, 罗枭, 张朋朋, 刘永梅, 叶小飞, 郭晓晶, 陈霞, 贺佳. 基于主动监测系统的免疫检查点抑制剂心肌炎不良反应探索[J]. 中国药物警戒, 2023, 20(6): 634-638.
[12]	辛雨濛, 卢天公, 孙震晓. 甘草干姜汤对顺铂所致巨噬细胞毒性的保护作用[J]. 中国药物警戒, 2023, 20(6): 661-670.
[13]	李容容, 李盟, 苟悦, 罗琼, 吕桦, 孙鑫, 刘成海. 113例抗肿瘤药物相关肝损伤的临床特点及危险因素分析[J]. 中国药物警戒, 2023, 20(5): 505-510.
[14]	罗世书, 屈杰, 周楠, 徐翠香, 刘屹, 张丽洁, 王建华. 289例单克隆抗体抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(4): 444-448.
[15]	焦福智, 陈雅蕊, 姬薇, 郝建朋, 关泉林. PD-1抑制剂联合化疗一线新辅助治疗局部进展期胃腺癌的近期疗效及安全性评估[J]. 中国药物警戒, 2023, 20(3): 301-305.